171 related articles for article (PubMed ID: 35242779)
1. Maintenance With Hypomethylating Agents After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.
Kungwankiattichai S; Ponvilawan B; Roy C; Tunsing P; Kuchenbauer F; Owattanapanich W
Front Med (Lausanne); 2022; 9():801632. PubMed ID: 35242779
[TBL] [Abstract][Full Text] [Related]
2. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.
Bewersdorf JP; Allen C; Mirza AS; Grimshaw AA; Giri S; Podoltsev NA; Gowda L; Cho C; Tallman MS; Zeidan AM; Stahl M
Transplant Cell Ther; 2021 Dec; 27(12):997.e1-997.e11. PubMed ID: 34551341
[TBL] [Abstract][Full Text] [Related]
3. Maintenance therapy with hypomethylating agents for patients with acute myeloid leukemia in first remission not eligible for allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
Sherban A; Raanani P; Gurion R; Wolach O; Gafter-Gvili A
Leuk Res; 2022 Feb; 113():106773. PubMed ID: 35066294
[TBL] [Abstract][Full Text] [Related]
4. Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia.
Schroeder T; Wegener N; Lauseker M; Rautenberg C; Nachtkamp K; Schuler E; Kondakci M; Haas R; Germing U; Kobbe G
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1550-1559. PubMed ID: 30880268
[TBL] [Abstract][Full Text] [Related]
5. FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: A meta-analysis.
Fei X; Zhang S; Gu J; Wang J
Cancer Med; 2023 Mar; 12(6):6877-6888. PubMed ID: 36411731
[TBL] [Abstract][Full Text] [Related]
6. Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis.
Pasvolsky O; Shimony S; Yeshurun M; Shargian L; Wolach O; Raanani P; Gafter-Gvili A; Gurion R
Acta Oncol; 2021 Oct; 60(10):1335-1341. PubMed ID: 34325602
[TBL] [Abstract][Full Text] [Related]
7. Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Tong X; Li M; Jin J; Li Y; Li L; Peng Y; Huang L; Xu B; Meng F; Mao X; Huang L; Huang W; Zhang D
Int J Cancer; 2023 May; 152(10):2123-2133. PubMed ID: 36594582
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome.
Guillaume T; Thépot S; Peterlin P; Ceballos P; Bourgeois AL; Garnier A; Orvain C; Giltat A; François S; Bris YL; Fronteau C; Planche L; Chevallier P
Transplant Cell Ther; 2021 Oct; 27(10):839.e1-839.e6. PubMed ID: 34224913
[TBL] [Abstract][Full Text] [Related]
9. Impact of treatments before allogeneic hematopoietic stem cell transplantation in patients with higher-risk myelodysplastic syndrome.
Zhang Y; Liu C; Zhang R; Shi Y; Li X; Yu J; Wan D; Xie X
Leuk Res; 2023 Jan; 124():106997. PubMed ID: 36502583
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Du Y; Li C; Zhao Z; Liu Y; Zhang C; Yan J
BMC Cancer; 2023 Aug; 23(1):764. PubMed ID: 37592239
[TBL] [Abstract][Full Text] [Related]
11. Hypomethylating agent-based post-transplant strategies to maximize the outcome of high-risk acute myeloid leukemia after allogeneic stem cell transplantation.
Baek DW; Kim J; Cho HJ; Moon JH; Sohn SK
Expert Rev Hematol; 2020 Sep; 13(9):959-969. PubMed ID: 32731765
[TBL] [Abstract][Full Text] [Related]
12. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
13. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
14. Charlson comorbidity index predicts outcomes of elderly after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome.
Chien SH; Yao M; Li CC; Chang PY; Yu MS; Huang CE; Tan TD; Lin CH; Yeh SP; Li SS; Wang PN; Liu YC; Gau JP
J Formos Med Assoc; 2021 Dec; 120(12):2144-2152. PubMed ID: 33423899
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Li L; Zhang R; Cao W; Bian Z; Qin Y; Guo R; Zhang S; Peng Y; Wan D; Ma W
Leuk Lymphoma; 2023 Dec; 64(13):2113-2122. PubMed ID: 37732615
[TBL] [Abstract][Full Text] [Related]
16. Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents.
Martino M; Fedele R; Moscato T; Ronco F
Curr Cancer Drug Targets; 2013 Jul; 13(6):661-9. PubMed ID: 23713435
[TBL] [Abstract][Full Text] [Related]
17. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome.
Cao J; Pei R; Lu Y; Zheng Z; Yuan Z; Li D; Zhang P; Liu X; Chen D; Du X; Chen L; Li S; Ye P; Wang T
Curr Res Transl Med; 2023; 71(1):103360. PubMed ID: 36427418
[TBL] [Abstract][Full Text] [Related]
19. No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome.
Sohn SK; Moon JH; Lee IH; Ahn JS; Kim HJ; Chung JS; Shin HJ; Park SW; Lee WS; Lee SM; Kim H; Lee HS; Kim YS; Cho YY; Bae SH; Lee JH; Kim SH; Song IC; Kwon JH; Lee YJ
Korean J Intern Med; 2018 Nov; 33(6):1194-1202. PubMed ID: 29232940
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
